These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 38807)

  • 21. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients?
    Levin H; Chengappa KN; Kambhampati RK; Mahdavi N; Ganguli R
    J Clin Psychiatry; 1992 Jul; 53(7):248-51. PubMed ID: 1353492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models.
    Casey DE
    Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821
    [No Abstract]   [Full Text] [Related]  

  • 25. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
    Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
    Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
    Cohen JD; Van Putten T; Marder S; Berger PA; Stahl SM
    J Clin Psychopharmacol; 1987 Oct; 7(5):324-9. PubMed ID: 2890671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl)].
    Gaebel W; Pietzcker A; Poppenberg A
    Pharmacopsychiatria; 1981 Sep; 14(5):180-8. PubMed ID: 6117091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A morphanthridine derivative in schizophrenic patients -- lack of extrapyramidal symptoms.
    Angrist B; Rotrosen J; Aronson M; Gershon S
    Curr Ther Res Clin Exp; 1976 Jul; 20(1):94-8. PubMed ID: 8281
    [No Abstract]   [Full Text] [Related]  

  • 36. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [20 years experience with chlorprothixene (author's transl)].
    Ravn J; Scharff A; Aaskoven O
    Pharmakopsychiatr Neuropsychopharmakol; 1980 Jan; 13(1):34-40. PubMed ID: 7367466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluphenazine plasma levels, dosage, efficacy, and side effects.
    Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
    Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced extrapyramidal side-effects in Egyptian schizophrenic patients.
    Okasha A; El Okbi H; Sadek A; Lotiaf F; Ashour AM
    Egypt J Psychiatry; 1979 Oct; 2(2):191-7. PubMed ID: 45368
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.